Traws Pharma SEC Filings

Traws Pharma (TRAW) reported an insider equity award. Chief Operating Officer and Director Nikolay Savchuk was granted a stock option for 22,435 shares at an exercise price of $3.01 on 10/12/2025.

The option vests 100% on 10/12/2026 and expires on 10/12/2035. The filing lists the holdings as Direct (D). This is a routine compensatory grant disclosed on Form 4.

Traws Pharma (TRAW) reported an insider equity award. On 10/01/2025, a company director received a stock option grant covering 15,609 shares of common stock at an exercise price of $1.89 per share.

The options expire on 10/01/2035 and were reported with a derivative security price of $0. The award vests over three years from the grant date: 33% on the first anniversary, 33% on the second, and 34% on the third. The filing lists direct (D) ownership following the transaction.

Traws Pharma (TRAW) filed a Form 3 for director John Leaman, reporting initial beneficial ownership status as of 10/01/2025.

The filing states that no securities are beneficially owned. This is a routine Section 16 compliance disclosure establishing the insider’s baseline holdings at the time he became a reporting person.

Traws Pharma (TRAW) announced a clinical milestone via an 8-K: on October 14, 2025, the company dosed the first subject in its Phase 2 study evaluating ratutrelvir, a ritonavir-free treatment candidate for newly diagnosed COVID subjects. The company furnished a press release as Exhibit 99.1.

This update signals progression into mid-stage testing for ratutrelvir, with details provided in the accompanying press release.

Traws Pharma, Inc. is soliciting proxies for its 2025 Annual Meeting to be held virtually on November 21, 2025. Stockholders of record as of October 2, 2025 may vote on the election of seven directors, ratification of KPMG LLP as auditor, non-binding advisory votes on executive compensation and pay-frequency, an amendment and restatement of the 2021 Incentive Compensation Plan, and a proposal to permit adjournment if additional votes are needed.

The Board recommends voting For each director nominee, For the auditor ratification, For the plan amendment, and Every Two Years for say-on-pay frequency. The plan amendment requests an increase of 1,500,000 shares and an extension of the plan term to the tenth anniversary of its effective date. There were 7,125,832 common shares outstanding on the record date; Series C preferred shares are non-voting for these proposals. Proxy materials and related Annual Report amendments will be available on or about October 8, 2025.

Schedule 13G filed for Traws Pharma, Inc. (TRAW) reports that Squadron Master Fund LP holds 372,374 shares (5.3%) and that Squadron Capital Management LLC and principals Matthew Sesterhenn and William Blank each report 420,501 shares (6.0%) based on 7,063,829 shares outstanding as of August 12, 2025. The filing states the shares are held by funds advised by Squadron Capital and that the adviser and the named partners disclaim beneficial ownership under Rule 13d-4. No party reports sole voting or dispositive power; all reported holdings are shared.

Traws Pharma, Inc. furnished an earnings press release announcing its financial results for the quarter ended June 30, 2025, and began using a new corporate investor presentation. The earnings release is furnished as Exhibit 99.1 and the presentation as Exhibit 99.2, and the presentation will be posted on the company website.

The disclosure in Item 7.01 is incorporated by reference into Item 2.02 but is explicitly furnished, not filed, and therefore is not subject to Section 18 liabilities or automatically incorporated by reference in other filings unless specifically referenced. The Current Report and its exhibits include customary forward‑looking statements and a risk disclaimer. The 8‑K body does not contain numeric financial results; investors must review Exhibits 99.1 and 99.2 for the full figures and context.